Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China
ConclusionFrom the perspective of the Chinese healthcare system,CYP2D6*10 pharmacogenetic testing was cost effective for postmenopausal women with ER-positive early breast cancer.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | China Health | Drugs & Pharmacology | Endocrine Therapy | Genetics | Study | Tamoxifen | Women